These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33258331)

  • 1. Implantable Cardioverter-defibrillator Utilization and Its Outcomes in Korea: Data from Korean Acute Heart Failure Registry.
    Cho Y; Cho SY; Oh IY; Lee JH; Park JJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Korean Med Sci; 2020 Nov; 35(46):e397. PubMed ID: 33258331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.
    Ruwald MH; Solomon SD; Foster E; Kutyifa V; Ruwald AC; Sherazi S; McNitt S; Jons C; Moss AJ; Zareba W
    Circulation; 2014 Dec; 130(25):2278-86. PubMed ID: 25301831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%.
    Al-Khatib SM; Hellkamp AS; Fonarow GC; Mark DB; Curtis LH; Hernandez AF; Anstrom KJ; Peterson ED; Sanders GD; Al-Khalidi HR; Hammill BG; Heidenreich PA; Hammill SC
    JAMA; 2014 Jun; 311(21):2209-15. PubMed ID: 24893088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes.
    Bilchick KC; Wang Y; Curtis JP; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Levy WC
    J Am Heart Assoc; 2022 Jul; 11(13):e023743. PubMed ID: 35766293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.
    Al-Khatib SM; Hellkamp A; Bardy GH; Hammill S; Hall WJ; Mark DB; Anstrom KJ; Curtis J; Al-Khalidi H; Curtis LH; Heidenreich P; Peterson ED; Sanders G; Clapp-Channing N; Lee KL; Moss AJ
    JAMA; 2013 Jan; 309(1):55-62. PubMed ID: 23280225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.
    Providência R; Marijon E; Lambiase PD; Bouzeman A; Defaye P; Klug D; Amet D; Perier MC; Gras D; Algalarrondo V; Deharo JC; Leclercq C; Fauchier L; Babuty D; Bordachar P; Sadoul N; Piot O; Boveda S
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients: Insight From the Resynchronization in Ambulatory Heart Failure Trial.
    Sapp JL; Parkash R; Wells GA; Yetisir E; Gardner MJ; Healey JS; Thibault B; Sterns LD; Birnie D; Nery PB; Sivakumaran S; Essebag V; Dorian P; Tang AS
    Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28292754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.
    Jilek C; Lewalter T; Pauschinger M; von Scheidt W; Frankenstein L; Pfister O; Hambrecht R; Bruder O; Brachmann J; Hartmann A; Strasser R; Hochadel M; Senges J
    Clin Res Cardiol; 2020 Jan; 109(1):115-123. PubMed ID: 31236690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.
    Wilcox JE; Fonarow GC; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
    Circ Heart Fail; 2014 Jan; 7(1):146-53. PubMed ID: 24178311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.
    Zeitler EP; Hellkamp AS; Schulte PJ; Fonarow GC; Hernandez AF; Peterson ED; Sanders GD; Yancy CW; Al-Khatib SM
    Circ Heart Fail; 2016 Jan; 9(1):e002630. PubMed ID: 26758365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
    Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure.
    Chia YMF; Teng TK; Tan ESJ; Tay WT; Richards AM; Chin CWL; Shimizu W; Park SW; Hung CL; Ling LH; Ngarmukos T; Omar R; Siswanto BB; Narasimhan C; Reyes EB; Yu CM; Anand I; MacDonald MR; Yap J; Zhang S; Finkelstein EA; Lam CSP
    Circ Cardiovasc Qual Outcomes; 2017 Nov; 10(11):. PubMed ID: 29150533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable Cardioverter Defibrillator Therapy in Patients with Acute Decompensated Heart Failure with Reduced Ejection Fraction: An Observation from the KCHF Registry.
    Hata R; Kato T; Yaku H; Morimoto T; Kawase Y; Yamamoto E; Inuzuka Y; Tamaki Y; Ozasa N; Yoshikawa Y; Kitai T; Yamashita Y; Iguchi M; Nagao K; Morinaga T; Furukawa Y; Kadota K; Sato Y; Kimura T
    J Cardiol; 2021 Mar; 77(3):292-299. PubMed ID: 33191081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Implantable Cardioverter-Defibrillator Therapy and Mortality Prediction Model for Effective Primary Prevention in Korean Patients.
    Bae MH; Cho Y; Hwang J; Park HS; Han S; Lee YS; Cho HJ; Jung BC; Lee CH; Hyun DW; Park JS; Ahn J; Kim KH; Shin DG
    J Korean Med Sci; 2020 Mar; 35(9):e49. PubMed ID: 32141247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.
    Lee TC; Qian M; Mu L; Di Tullio MR; Graham S; Mann DL; Nakanishi K; Teerlink JR; Lip GYH; Freudenberger RS; Sacco RL; Mohr JP; Labovitz AJ; Ponikowski P; Lok DJ; Estol C; Anker SD; Pullicino PM; Buchsbaum R; Levin B; Thompson JLP; Homma S; Ye S;
    ESC Heart Fail; 2019 Apr; 6(2):297-307. PubMed ID: 30816013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.